He only successful therapeutic strategy; however, patients with unresectable or metastatic Bookmarking site
1
He only successful therapeutic strategy; however, patients with unresectable or metastatic disease survived only a median of 18-24 months after diagnosis [4,5]. Those patients with widespread metastatic disease have an estimated 9 month overall survival [6]. The development of the selective kinase inhibitor imatinib mesylate (also known as Gleevec) has dramatically altered the treatment strategies